US 12,460,005 B2
Binding molecules specific for claudin 18.2, compositions and methods thereof, for treatment of cancer and other diseases
Guidong Zhu, Gurnee, IL (US); Jingdong Ye, Vernon Hills, IL (US); Jingdong Qin, Woodridge, IL (US); and Jichun Ma, Germantown, MD (US)
Assigned to SparX Bioscience Limited, Tortola (VG)
Filed by SPARX BIOSCIENCE LIMITED, Tortola (VG)
Filed on Sep. 19, 2022, as Appl. No. 17/933,350.
Application 17/933,350 is a continuation of application No. 16/727,554, filed on Dec. 26, 2019, granted, now 11,447,551.
Claims priority of provisional application 62/786,012, filed on Dec. 28, 2018.
Prior Publication US 2023/0087790 A1, Mar. 23, 2023
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12N 15/85 (2006.01); G01N 33/00 (2006.01)
CPC C07K 16/2827 (2013.01) [C12N 15/85 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C12N 2015/8518 (2013.01)] 10 Claims
 
1. An antibody that binds Claudin 18.2 (anti-CLDN18.2 antibody), comprising
(a) a heavy chain that comprises a heavy chain variable region (VH), wherein the VH comprises a heavy chain complementarity determining region (CDR) 1 comprising the amino acid sequence of RYAFTNYLIE (SEQ ID NO: 55), a heavy chain CDR2 comprising the amino acid sequence of MINPGSGGTHYNEKFKV (SEQ ID NO: 56), and a heavy chain CDR3 comprising the amino acid sequence of GGFGNSFAY (SEQ ID NO: 50); and
(b) a light chain that comprises a light chain variable region (VL), wherein the VL comprises a light chain CDR1 comprising the amino acid sequence of KSSQSLLNGGNLKNYLT (SEQ ID NO: 52), a light chain CDR2 comprising the amino acid sequence of WASTRES (SEQ ID NO: 45), and light chain CDR3 comprising the amino acid sequence of QNGYFYPYT (SEQ ID NO: 53).